| Name | Title | Contact Details |
|---|
NovoLogix is a cutting-edge Medical Pharmacy Benefit Management company.
Care New England Health System (CNE) and its member institutions—Butler Hospital, Women & Infants Hospital, Kent Hospital, Memorial Hospital, VNA of Care New England, The Providence Center and Care New England Wellness Center—are trusted organizations fueling the latest advances in medical research, attracting the nation`s top specialty-trained doctors, and honing renowned services and innovative programs to engage in the important discussions people need to have about their health. Backed by a broad range of services—primary care, surgery, cardiovascular care, oncology, psychiatry, behavioral health, newborn pediatrics and the full spectrum of women`s health services—CNE is reinventing the way health care is delivered, partnering with our patients to provide the best care possible while working to create a community of healthier people. To that end, we are committed to a culture of accountability, caring and teamwork. We called it ACT values. These values were not defined by senior management but through a comprehensive process with our employees who identified these values as tangible and important to the cohesiveness of the entire organization. They are embedded into everything we do, working with patients and their families, and with each other.
g.b.cooley hospital service district is a Monroe, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
United American Healthcare Corporation is a Detroit, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.